Cantargia Logo

Cantargia

Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.

CANTA | ST

Overview

Corporate Details

ISIN(s):
SE0006371126 (+3 more)
LEI:
549300GKWRT7RXI4VS85
Country:
Sweden
Address:
Scheelevägen 27, 223 63 Lund

Description

Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-05 07:30
Cantargia rapporterar övergripande överlevnadsresultat från TRIFOUR
Swedish 112.8 KB
2025-12-05 07:30
Cantargia Provides Update on Overall Survival Data from TRIFOUR
English 113.6 KB
2025-11-19 07:00 Swedish 1.2 MB
2025-11-19 07:00 English 1.2 MB
2025-11-12 08:45
Cantargia presents Nomination Committee ahead of 2026 AGM
English 94.9 KB
2025-11-12 08:45
Cantargia presenterar valberedning inför årsstämman 2026
Swedish 95.0 KB
2025-10-02 07:30
Cantargia utser Dr Wolfram Dempke till Chief Medical Officer
Swedish 102.8 KB
2025-10-02 07:30
Cantargia appoints Dr. Wolfram Dempke as Chief Medical Officer
English 103.2 KB
2025-09-11 07:30
Cantargia closes the acquisition of CAN10 by Otsuka
English 104.2 KB
2025-09-11 07:30
Cantargia slutför Otsukas förvärv av CAN10
Swedish 103.9 KB
2025-08-21 07:00 Swedish 3.5 MB
2025-08-21 07:00 English 3.5 MB
2025-08-18 18:25
Cantargia utnämner Dr Hilde Steineger till verkställande direktör
Swedish 107.1 KB
2025-08-18 18:25
Cantargia appoints Dr Hilde Steineger as Chief Executive Officer
English 107.8 KB
2025-07-17 21:30
Cantargia announces preliminary topline efficacy results from the phase 2 TRIFO…
English 117.3 KB

Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cantargia

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cantargia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-07-28 Thoas Fioretos Other Other 78,400 294,000.00 SEK
2022-07-28 Bengt Jöndell Other Other 75,999 284,996.25 SEK
2022-07-28 David Liberg Other Other 7,464 27,990.00 SEK
2022-07-28 Liselotte Larsson Other Other 21,066 78,997.50 SEK
2022-07-28 Gunnar Magnus Severus Modée Persson Other Other 44,976 168,660.00 SEK
2022-07-27 Magnus Nilsson Other Buy 37,500 193,875.00 SEK
2022-07-27 Nedjad Losic Other Other 5,332 19,995.00 SEK
2022-07-27 Lars Thorsson Other Other 50,414 189,052.50 SEK
2022-07-27 Magnus Nilsson Other Other 16,666 62,497.50 SEK
2022-07-27 Susanne Lagerlund Other Other 1,533 5,748.75 SEK

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.